Status:
UNKNOWN
Expression and Clinical Significance of IGHD in Pancreatic Cancer
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Gene Expression
Eligibility:
All Genders
18-80 years
Brief Summary
Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular marke...
Detailed Description
Methods：The expressions of IGHD in peripheral blood of about 30 patients with pancreatic cancer and more than 30 healthy controls were detected by qRT-PCR, and the differences of IGHD were analyzed.Th...
Eligibility Criteria
Inclusion
- Patients with pathologically confirmed pancreatic cancer
Exclusion
- noperable patients
- other malignant tumors
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05327400
Start Date
May 1 2022
End Date
October 31 2023
Last Update
September 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Nantong University
Nantong, Jiangsu, China